Both groups demonstrated efficacy through 52weeks of treatment relative to baseline pretabalumab disease activity based on American College of Rheumatology criteria improvement 20 % , 50 % and 70 % ; European League against Rheumatism Responder Index in 28 joints ; Disease Activity Score in 28 joints-C-reactive protein ; and Health Assessment Questionnaire-Disability Index .